Key result
Intra-arterial tenecteplase post-EVT increases 90-day excellent neurological outcomes by ~44% over standard care.
Why the study?
Does intra-arterial tenecteplase improve excellent neurological outcome at 90 days in patients with acute LVO stroke after successful endovascular therapy?
RCT (n=256)
Open-label, blinded end point
randomized
Yes
Does intra-arterial tenecteplase improve excellent neurological outcome at 90 days in patients with acute LVO stroke after successful endovascular therapy?
Relative Risk: 1.44 (95% CI 1.06–1.95)
Absolute Event Rate: 40.5% vs 26.4%
p-value: p=0.02
No takes yet. Share an insight, caveat, or question.
Intra-arterial tenecteplase administered after successful endovascular therapy for acute LVO stroke significantly improved the likelihood of an excellent neurological outcome at 90 days without increasing the risk of symptomatic intracranial hemorrhage or mortality.
Miao et al. (2025) conducted an RCT in Acute large vessel occlusion (LVO) stroke (n=256). Intra-arterial tenecteplase vs. Standard medical treatment was evaluated on Excellent outcome at 90 days, defined as modified Rankin Scale (mRS) score of 0 to 1 (RR 1.44, 95% CI 1.06-1.95, p=0.02). Intra-arterial tenecteplase after successful endovascular therapy increased excellent neurological outcome at 90 days compared with standard treatment (RR 1.44; 95% CI 1.06-1.95; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: